DERAIL-LVV

  • Research type

    Research Study

  • Full title

    Dual Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV)

  • IRAS ID

    348224

  • Contact name

    Neeraj Dhaun

  • Contact email

    bean.dhaun@ed.ac.uk

  • Sponsor organisation

    University of Edinburgh

  • Duration of Study in the UK

    3 years, 0 months, 1 days

  • Research summary

    Large vessel vasculitis (LVV) is a condition which involves inflammation of medium- and large-sized blood vessels. Over time, this inflammation can permanently damage the blood vessels leading to pain, vision loss, and blood vessel rupture. Treatment is usually effective in the short term. However, the disease is a lifelong condition, and relapse is common. Longer-term, affected patients have a high risk of cardiovascular disease, including heart attacks and strokes. Currently, little is known about why this is the case, and so little can be done to reduce this risk.

    The ‘endothelium’ is an important layer within blood vessels which controls their response to stress. If the endothelium is damaged, it can increase the risk of cardiovascular disease. My previous work has suggested that a damaged endothelium may be at least partly responsible for the increased cardiovascular disease risk in LVV. If this is the case, then drugs which improve the endothelium may also be able to reduce the risk of cardiovascular disease.

    Thus, this study aims to assess the function of the endothelium in detail in patients with LVV, and to see if this can be improved with a drug which targets the endothelium called 'bosentan'. We will recruit a group of patients with LVV and a group of similarly aged people without LVV. First, we will assess the function of the endothelium in both groups; next, the LVV group will receive bosentan for a period of 6 weeks. Following this, we will assess the function of the endothelium again.

    We believe that patients with LVV will have a poorly working endothelium compared to similarly aged people without LVV, and that this will improve after 6 weeks of bosentan treatment.

  • REC name

    North East - Newcastle & North Tyneside 1 Research Ethics Committee

  • REC reference

    25/NE/0011

  • Date of REC Opinion

    4 Feb 2025

  • REC opinion

    Further Information Favourable Opinion